Sanofi and Zaihuan cooperate to develop new anti-inflammatory drugs, which are approved by the European Union

[chinapharma.com news] kevzara, a new anti-inflammatory drug developed by Sanofi, a French pharmaceutical giant, and regeneron, a partner, has been approved by the European Union Kevzara is a humanized monoclonal antibody drug targeting IL-6 receptor Specifically, CHMP recommends that kevzara in combination with methotrexate (MTX) be approved for use in adults with moderate to severe active RA who have previously received one or more modified antirheumatic drugs (DMARDs) for the treatment of insufficient or intolerant remission (picture source: Baidu picture) kevzara can be used in combination with methotrexate (MTX); kevzara can also be used alone if patients are intolerant or contraindicated to methotrexate The recommended dose of kevzara is 200mg subcutaneously injected once every two weeks In some cases, the dose can be reduced from 200mg to 150mg in order to manage specific laboratory abnormalities, including neutropenia, thrombocytopenia and liver enzyme elevation CHMP recommends approval of kevzara, which is based on the data of the global saril-ra phase III clinical project, which includes seven phase III clinical studies involving more than 3300 adult patients with active moderate to severe RA, most of whom have insufficient response to the previous treatment plan SARIL-RA The phase III clinical project focuses on an adult population of active moderate to severe rheumatoid arthritis (RA) patients with insufficient response to disease modifying antirheumatic drugs (DMARDs, including methotrexate) or tumor necrosis factor - α (TNF - α) inhibitors, and aims to evaluate the subcutaneous injection of sarilumab as monotherapy or in combination with traditional disease modifying antirheumatic drugs (DMARDs), including methotrexate, in a wide range of patients The efficacy and safety of methotrexate in improving symptoms and signs of disease and inhibiting the progress of RA radiology The European Commission (EC) is expected to make a final review decision on kevzara's application for marketing authorization (MAA) in Europe in the coming months In Europe, there are about 2.9 million patients with rheumatoid arthritis (RA), whose symptoms include joint pain, swelling, stiffness and fatigue, which can seriously affect their daily lives It is worth mentioning that kevzara was approved by Health Canada in February this year This approval is also the regulatory approval of kevzara's harvest worldwide At present, sarilumab is also under review by the United States and the European Union, and the results are expected to be obtained this year The industry is very optimistic about the business prospects of sarilumab Previously, evaluatepharma, a well-known global pharmaceutical market research institution, released a report, which predicted that the sales peak of sarilumab in 2020 would reach 1.8 billion US dollars.